Abstract
The German Hodgkin Study Group (GHSG) HD11 trial established 4 cycles of ABVD and 30 Gy of radiation therapy (RT) as a standard for early-stage, unfavorable Hodgkin lymphoma (UF HL). HD11 also demonstrated that with 4 cycles of baseline BEACOPP, 20 Gy is as efficacious as 30 Gy. Additional cycles of ABVD may also allow for a reduction in RT dose. At our institution, patients often receive more than 4 cycles of ABVD for UF HL. If a complete response (CR) by positron emission tomography (PET) is achieved, ∼20 Gy of consolidation RT is typically administered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
